Steris Plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6B+10.6% YoYTTM through 30 Jun 2026
Net Income $805M+31.0% YoYTTM through 30 Jun 2026
Free Cash Flow $925.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 44.2% |
| EBITDA Margin | 27.0% |
| Operating Margin | 18.6% |
| Net Margin | 13.3% |
Returns
10.9%ROE
7.5%ROA
9.3%ROIC
Balance Sheet Health
Debt / Equity0.25x
Current Ratio2.09x
Net Debt$1.4B
Cash & Equivalents$482.3M
Quality Metrics
Altman Z-Score4.93
Piotroski F-Score8 / 9
FCF Margin15.3%
Rule of 4020.9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2026: $5.9B
Diluted EPS$7.93TTMFY2026: $7.93
Dividend
$1.26Per share, FY20261.21%Yield-5.4%5-yr growth
Capital Allocation
R&D Spend$115.1M
Capex Intensity6.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Healthcare | $4.2B | +8.5% | View detailsExpected to benefit from tuck-in acquisitions and sustained global procedure volumes. |
| Applied Sterilization Technologies (AST) | $1.1B | +9.6% | View detailsAST segment continues to see strong service revenue growth, though capital equipment remains soft. |
| Life Sciences | $588.8M | +8.6% | View detailsSustained demand for consumables and services expected to drive steady growth. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.